Point72 Asset Management
RNAM

Point72 Asset Management’s Avidity Biosciences RNAM Stock Holding History

Point72 Asset Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-60,584
Closed -$387K – 2715
2023
Q3 		$387K Buy
+60,584
New +$522K ﹤0.01% 1589
2021
Q4 		– Sell
-201,000
Closed -$4.95M – 1266
2021
Q3 		$4.95M Buy
+201,000
New +$4.37M 0.02% 666

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Point72 Asset Management's RNAM Position: Q4 2023 in Review

Point72 Asset Management sold out of Avidity Biosciences (RNAM) in Q4 2023, closing a stake of 60,584 shares — an estimated $387K sold.

Point72 Asset Management first reported a position in RNAM in Q3 2021 and held it in 2 quarters. The position peaked at $4.95M in Q3 2021. 144 funds tracked by Wall St. Rank hold RNAM as of Q4 2023.

  • Point72 Asset Management reported no remaining Avidity Biosciences position as of Q4 2023 after selling out during the quarter.
  • Point72 Asset Management sold 60,584 Avidity Biosciences shares in Q4 2023, an estimated $387K.
  • Point72 Asset Management first reported a position in Avidity Biosciences in Q3 2021 and held it in 2 quarters.
  • Point72 Asset Management's Avidity Biosciences position peaked at $4.95M in Q3 2021.
  • 144 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2023.

Based on Point72 Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.